Standout Papers

Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postm... 2000 2026 2008 2017 720
  1. Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial (2000)
    Jean‐Marc Nabholtz, Aman U. Buzdar et al. Journal of Clinical Oncology
  2. Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study (2000)
    Jacques Bonneterre, Beat Thürlimann et al. Journal of Clinical Oncology

Immediate Impact

1 by Nobel laureates 10 from Science/Nature 79 standout
Sub-graph 1 of 15

Citing Papers

Pan-cancer whole-genome comparison of primary and metastatic solid tumours
2023 StandoutNature
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial
2023 Standout
1 intermediate paper

Works of Alan Webster being referenced

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status
2014
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women
2003

Author Peers

Author Last Decade Papers Cites
Alan Webster 3368 2485 3337 2651 33 5.7k
Dean B. Evans 2103 986 2686 2003 106 5.5k
Ivana Šestak 3202 1287 3976 3962 107 7.3k
Mark L. Steinberg 1973 777 1456 1381 50 3.3k
Elizabeth Tan-Chiu 3109 1042 5057 3183 47 8.5k
M Baum 2328 565 2001 1558 33 3.5k
Hideki Endoh 1717 2718 2838 2426 52 7.5k
D. Craig Allred 2348 908 4448 3363 51 7.4k
Tommy� Fornander 2051 1166 2833 2556 133 6.4k
T.J. Powles 3339 687 3718 2311 81 6.8k
Janet Wolter 1252 2290 9010 2869 30 12.1k

All Works

Loading papers...

Rankless by CCL
2026